EU Decision Time For Orphan Drugs Marstacimab, Serplulimab And Mirvetuximab Soravtansine

 
• By Eliza Slawther

The European Medicines Agency is this week expected to decide whether to recommend for pan-EU marketing approval for Pfizer’s marstacimab, Henlius Biotech’s serplulimab and ImmunoGen’s mirvetuximab soravtansine.

Decision paths
• Source: Shutterstock

More from EU CHMP

More from Pink Sheet